» Articles » PMID: 34807312

Relevance of Mitochondrial Dysfunction in Heart Disease Associated with Insulin Resistance Conditions

Overview
Journal Pflugers Arch
Specialty Physiology
Date 2021 Nov 22
PMID 34807312
Citations 1
Authors
Affiliations
Soon will be listed here.
Abstract

Insulin resistance plays a key role in the development and progression of obesity, diabetes, and their complications. Moreover, insulin resistance is considered the principal link between metabolic diseases and cardiovascular diseases. Heart disease associated with insulin resistance is one of the most important consequences of both obesity and diabetes, and it is characterized by impaired cardiac energetics, diastolic dysfunction, and finally heart failure. Mitochondrion plays a key role in cell energy homeostasis and is the main source of reactive oxygen species. Obesity and diabetes are associated with alterations in mitochondrial function and dynamics. Mitochondrial dysfunction is characterized by changes in mitochondrial respiratory chain with reduced ATP production and elevated reactive oxygen species production. These mitochondrial alterations together with inflammation contribute to the development and progression of heart disease under insulin resistance conditions. Finally, numerous miRNAs participate in the regulation of energy substrate metabolism, reactive oxygen species production, and apoptotic pathways within the mitochondria. This notion supports the relevance of interactions between miRNAs and mitochondrial dysfunction in the pathophysiology of metabolic heart disease.

Citing Articles

The Aryl Hydrocarbon Receptor (AhR) Is a Novel Gene Involved in Proper Physiological Functions of Pancreatic β-Cells.

Bin Eshaq S, Taneera J, Anjum S, Mohammed A, Semreen M, Alzoubi K Cells. 2025; 14(1.

PMID: 39791758 PMC: 11720184. DOI: 10.3390/cells14010057.


Highlighting the novel effects of high-intensity interval training on some histopathological and molecular indices in the heart of type 2 diabetic rats.

Rami M, Rahdar S, Ahmadi Hekmatikar A, Daud D Front Endocrinol (Lausanne). 2023; 14:1175585.

PMID: 37274326 PMC: 10235768. DOI: 10.3389/fendo.2023.1175585.

References
1.
Kwasny C, Manuwald U, Kugler J, Rothe U . Systematic Review of the Epidemiology and Natural History of the Metabolic Vascular Syndrome and its Coincidence with Type 2 Diabetes Mellitus and Cardiovascular Diseases in Different European Countries. Horm Metab Res. 2017; 50(3):201-208. DOI: 10.1055/s-0043-122395. View

2.
Mendrick D, Diehl A, Topor L, Dietert R, Will Y, La Merrill M . Metabolic Syndrome and Associated Diseases: From the Bench to the Clinic. Toxicol Sci. 2017; 162(1):36-42. PMC: 6256950. DOI: 10.1093/toxsci/kfx233. View

3.
Nishida K, Otsu K . Inflammation and metabolic cardiomyopathy. Cardiovasc Res. 2017; 113(4):389-398. DOI: 10.1093/cvr/cvx012. View

4.
Ormazabal V, Nair S, Elfeky O, Aguayo C, Salomon C, A Zuniga F . Association between insulin resistance and the development of cardiovascular disease. Cardiovasc Diabetol. 2018; 17(1):122. PMC: 6119242. DOI: 10.1186/s12933-018-0762-4. View

5.
Riehle C, Abel E . Insulin Signaling and Heart Failure. Circ Res. 2016; 118(7):1151-69. PMC: 4833475. DOI: 10.1161/CIRCRESAHA.116.306206. View